323 related articles for article (PubMed ID: 21629744)
1. Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?
Stintzing S; Kemmerling R; Kiesslich T; Alinger B; Ocker M; Neureiter D
J Biomed Biotechnol; 2011; 2011():214143. PubMed ID: 21629744
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic changes in the myelodysplastic syndrome.
Issa JP
Hematol Oncol Clin North Am; 2010 Apr; 24(2):317-30. PubMed ID: 20359628
[TBL] [Abstract][Full Text] [Related]
3. [Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome].
Zhi YQ; Guo SQ; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):792-5. PubMed ID: 22739204
[TBL] [Abstract][Full Text] [Related]
4. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
5. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Gore SD; Baylin S; Sugar E; Carraway H; Miller CB; Carducci M; Grever M; Galm O; Dauses T; Karp JE; Rudek MA; Zhao M; Smith BD; Manning J; Jiemjit A; Dover G; Mays A; Zwiebel J; Murgo A; Weng LJ; Herman JG
Cancer Res; 2006 Jun; 66(12):6361-9. PubMed ID: 16778214
[TBL] [Abstract][Full Text] [Related]
6. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.
Santini V; Melnick A; Maciejewski JP; Duprez E; Nervi C; Cocco L; Ford KG; Mufti G
Crit Rev Oncol Hematol; 2013 Nov; 88(2):231-45. PubMed ID: 23838480
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Quintás-Cardama A; Santos FP; Garcia-Manero G
Leukemia; 2011 Feb; 25(2):226-35. PubMed ID: 21116282
[TBL] [Abstract][Full Text] [Related]
9. More is better: combination therapies for myelodysplastic syndromes.
Ornstein MC; Mukherjee S; Sekeres MA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
[TBL] [Abstract][Full Text] [Related]
10. Deacetylase inhibitors for the treatment of myelodysplastic syndromes.
Jabbour E; Garcia-Manero G
Leuk Lymphoma; 2015 May; 56(5):1205-12. PubMed ID: 25058371
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
Collier CD; Getty PJ; Greenfield EM
Adv Exp Med Biol; 2020; 1258():55-75. PubMed ID: 32767234
[TBL] [Abstract][Full Text] [Related]
12. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
[TBL] [Abstract][Full Text] [Related]
13. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Griffiths EA; Gore SD
Semin Hematol; 2008 Jan; 45(1):23-30. PubMed ID: 18179966
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.
Dimicoli S; Jabbour E; Borthakur G; Kadia T; Estrov Z; Yang H; Kelly M; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2012 Jan; 87(1):127-9. PubMed ID: 22072492
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
16. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
17. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Figueroa ME; Skrabanek L; Li Y; Jiemjit A; Fandy TE; Paietta E; Fernandez H; Tallman MS; Greally JM; Carraway H; Licht JD; Gore SD; Melnick A
Blood; 2009 Oct; 114(16):3448-58. PubMed ID: 19652201
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.
Leone G; D'Alò F; Zardo G; Voso MT; Nervi C
Curr Med Chem; 2008; 15(13):1274-87. PubMed ID: 18537607
[TBL] [Abstract][Full Text] [Related]
20. Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy.
Oki Y; Issa JP
Int J Hematol; 2007 Nov; 86(4):306-14. PubMed ID: 18055336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]